BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)

  LSK BioPharma and Jiangsu Hengrui Medicine, Co., Ltd. today announced that the companies have entered into a global clinical collaboration in patients with advanced hepatocellular carcinoma

  October 21, 2018

   · 

  6 min read
• Biotech Beach

  Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress

  Clinical data in non-small cell lung cancer (NSCLC) and melanoma patients with CBL inactivating mutations treated with single agent sitravatinib demonstrate encouraging results

  October 21, 2018

   · 

  5 min read
• Biotech Bay

  Varian Unveils New Bravos Afterloader System for Brachytherapy Treatments

  Varian today announced the Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments.

  October 21, 2018

   · 

  2 min read
• Next Generation ExacTrac Broadens Clinical Workflows

  Market-leading technology now consolidates multiple spatial tracking technologies

  October 21, 2018

   · 

  6 min read
• Business

  New Members Appointed to National Safety Council Board of Directors

  Chairman Mark Vergnano welcomes nine new board members at nation’s largest annual safety gathering

  October 21, 2018

   · 

  4 min read
• Drug Development

  ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis

  Integrated safety analysis reflects long-term results from 3,492 treated patients for 7,860 patient-years of exposure

  October 21, 2018

   · 

  14 min read